Actinium Pharmaceuticals (Actinium Pharmaceuticals) Cash-to-Debt : 42.41 (As of Mar. 2024)

View and export this data going back to 2007. Start your Free Trial

What is Actinium Pharmaceuticals Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Actinium Pharmaceuticals's cash to debt ratio for the quarter that ended in Mar. 2024 was 42.41.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Actinium Pharmaceuticals could pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Actinium Pharmaceuticals's Cash-to-Debt or its related term are showing as below:

ATNM' s Cash-to-Debt Range Over the Past 10 Years
Min: 4.56 Med: 107.76 Max: No Debt
Current: 42.41

During the past 13 years, Actinium Pharmaceuticals's highest Cash to Debt Ratio was No Debt. The lowest was 4.56. And the median was 107.76.

ATNM's Cash-to-Debt is ranked better than
71.12% of 1541 companies
in the Biotechnology industry
Industry Median: 6.49 vs ATNM: 42.41

Actinium Pharmaceuticals Cash-to-Debt Historical Data

The historical data trend for Actinium Pharmaceuticals's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Actinium Pharmaceuticals Cash-to-Debt Chart

Actinium Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

6.48

86.13

251.06

42.20

36.29

Actinium Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															38.42	39.06	37.53	36.29	42.41

Competitive Comparison of Actinium Pharmaceuticals's Cash-to-Debt

For the Biotechnology subindustry, Actinium Pharmaceuticals's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Actinium Pharmaceuticals's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Actinium Pharmaceuticals's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Actinium Pharmaceuticals's Cash-to-Debt falls into.

Actinium Pharmaceuticals Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Actinium Pharmaceuticals's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	76.677	/	(0.541	+	1.572)
	=	36.29

Actinium Pharmaceuticals's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	84.057	/	(0.551	+	1.431)
	=	42.41

Actinium Pharmaceuticals (AMEX:ATNM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Actinium Pharmaceuticals Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Actinium Pharmaceuticals's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Actinium Pharmaceuticals (Actinium Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Actinium Pharmaceuticals Inc (AMEX:ATNM) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

7AY1:Germany

Address

275 Madison Avenue, 7th Floor, New York, NY, USA, 10016

Website

https://www.actiniumpharma.com

Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of innovative-targeted therapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest in order to kill those cells safely and effectively. Its most advanced products are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.

Executives

Sandesh Seth	director	300 E 93RD STREET, #20-B, NEW YORK NY 10128
Steve O'loughlin	officer: VP, Finance and Corporate Dev.	955 HARTMAN RUN ROAD, MORGANTOWN WV 26507
Dale L. Ludwig	officer: Chief Scientific Officer	21 FERNWOOD ROAD, ROCKAWAY NJ 07866-2028
Jeffrey W. Chell	director	521 MANDALAY AVENUE #708, CLEARWATER BEACH FL 33767
Ajit Shetty	director	643 ZEEDIJK, KNOKKE C9 8300
Anil Kapur	officer: Chief Commercial Officer	275 MADISON AVE, SUITE 702, NEW YORK NY 10016
Nitya G. Ray	officer: Executive Vice President	14 BAYBURY COURT, EAST HANOVER NJ 07936
Mark Stanley Berger	officer: Chief Medical Officer	140 RIVERSIDE DRIVE, APT. 9K, NEW YORK NY 10024
Memorial Sloan-kettering Cancer Center	10 percent owner	1275 YORK AVE., NEW YORK NY 10065
Sergio Traversa	director	138 CANTERBURY LN, BLUE BELL PA 19422
C. David Nicholson,	director	103 CHILDS ROAD, BASKIN RIDGE NJ 07092
Kaushik J Dave	director, officer: President and CEO	4 WATER STREET, EDISON NJ 08820
Richard I Steinhart	director	125 ELM STREET, NEW CANAAN CT 06840
Ahlb Holdings, Llc	10 percent owner	C/O MSKCC, 1275 YORK AVE., NEW YORK NY 10065
Actinium Holdings, Ltd.	10 percent owner	C/O /O STERLING MANAGEMENT, LTD., P.O. BOX HM 29, HAMILTON HM CX D0 00000